AlthoughHelicobacter pylori infection is both a common and a serious bacterial infection, antimicrobial therapies have rarely been optimized, are prescribed empirically, and provide inferior results compared with antimicrobial therapies for other common infectious diseases. In this Review, Rimbara and colleagues consider the available therapies for H. pyloriinfection, the problem of antimicrobial resistance and the role of susceptibility testing. They also provide practical guidance on the selection of optimal therapy and outline future research goals.
- Emiko Rimbara
- Lori A. Fischbach
- David Y. Graham
